Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults
Banda CG., Dzinjalamala F., Mukaka M., Mallewa J., Maiden V., Terlouw DJ., Lalloo DG., Khoo SH., Mwapasa V.
There are limited data on the pharmacokinetic and safety profiles of dihydroartemisinin-piperaquine (DHA-PQ) among human immunodeficiency virus-infected (HIV-positive [HIV + ]) individuals taking antiretroviral therapy (ART). In a two-step (parallel-group) pharmacokinetic trial with intensive blood sampling, we compared the area under the concentration-time curve from days 0 to 28 (AUC 0–28 days ) and the safety outcomes of piperaquine among malaria-uninfected HIV + adults.